Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018)

Historic Non-Current Deffered Revenue for Rocket Pharmaceuticals (RCKT) over the last 2 years, with Q4 2018 value amounting to $457000.0.

  • Rocket Pharmaceuticals' Non-Current Deffered Revenue rose 32710.28% to $457000.0 in Q4 2018 from the same period last year, while for Dec 2018 it was $457000.0, marking a year-over-year increase of 32710.28%. This contributed to the annual value of $457000.0 for FY2018, which is 32710.28% up from last year.
  • Latest data reveals that Rocket Pharmaceuticals reported Non-Current Deffered Revenue of $457000.0 as of Q4 2018, which was up 32710.28% from $438000.0 recorded in Q3 2018.
  • In the past 5 years, Rocket Pharmaceuticals' Non-Current Deffered Revenue ranged from a high of $598000.0 in Q1 2018 and a low of $107000.0 during Q4 2017